Start Date
July 1, 2020
Primary Completion Date
May 31, 2025
Study Completion Date
May 31, 2026
thryoid hormone T4 + oral potassium iodide (KI) for 42 days
Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
D5W - 5% dextrose water
Equivalent volume of infusion as study drug
Maria Fareri Childrens Hospital, Valhalla
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
New York Medical College
OTHER